Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart

Orthofix Medical Inc.

2026-Q1 EPS reported -$0.52 revenue$196,708,000

Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.
FY 2026 guidance reaffirmed: net sales $850M-$860M, adj. EBITDA $95M-$98M, positive FCF ex-legal settlements.
President, Global Spine Max Reinhardt to depart on/about June 12, 2026; role eliminated in realignment.
Key spine leaders (Bannigan, Sienkiewicz, Winge) now report directly to CEO; Fisher expands to Biologics.
M6 disc discontinuation impact fell to $0.3M in Q1 from $4.4M in Q1 2025.

item 2.02item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Max Reinhardt

President, Global Spine

Orthofix Medical Inc.

Effective: 2026-06-12
Filed: Apr 09, 2026 23:59 UTC

Max Reinhardt, the Company’s President, Global Spine, will be departing as an executive and employee on or about June 12, 2026.

Source: SEC EDGAR

accession 0001193125-26-148853

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.